Core Points - Dr. Nicholas Wernicki has been appointed as the new Dean of the Arts, Humanities, and Education School at American Public University System (APUS), effective May 22, 2025 [1][2] - Dr. Wernicki has extensive experience in academic leadership and workforce development, having held various roles at liberal arts colleges over the past decade [3] - He succeeds Dr. Michelle Newman, who served as Interim Dean, and joins a team of three other deans at APUS [4] Academic Background - Dr. Wernicki holds a Ph.D. in Philosophical and Theological Studies from Drew University, an M.Phil. in the same field, an M.A. in Liberal Studies from Villanova University, and a B.S. in Marketing from DeSales University [5] Institutional Overview - APUS has a 33-year history and a community of over 155,000 alumni from more than 80 countries, recognized for its innovative approach to online learning [6] - The institution is in the top 22% for students' return on educational investment among 4,396 colleges and universities nationwide, based on data from the Georgetown University Center on Education and the Workforce [6][8] - APUS is accredited by the Higher Learning Commission and is a wholly owned subsidiary of American Public Education, Inc. [7]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain best practices in content production and search engine optimization [5]

Core Insights - Aeva Technologies (AEVA) has gained attention due to its partnership with Swiss delivery company Loxo, leveraging its unique GPS-free localization technology [1][9] - Aeva's 4D LiDAR sensor, Atlas, provides real-time velocity and direction data, distinguishing it from traditional LiDAR systems [2][6] - The technology is particularly beneficial for Loxo's expansion into dense European cities where GPS signals are often unreliable [3][9] Aeva's Distinctive Velocity Advantage - Aeva's Atlas sensor measures velocity and direction directly, offering a clear understanding of surroundings without GPS [2][6] - This capability is crucial for autonomous delivery vehicles operating in environments with weak GPS signals [3][6] Comparison with Competitors - Competitors like Luminar Technologies (LAZR) and Ouster (OUST) focus on high-resolution, long-range sensing but lack built-in velocity detection [4][5] - Luminar's Iris sensor estimates motion through software, which may introduce lag in real-time responsiveness, while Ouster relies on external data [5][6] Market Position and Valuation - Aeva's shares have surged approximately 265% year to date, indicating strong market interest [8] - The company trades at a forward price-to-sales ratio of 33.36, significantly higher than the sector average, and carries a Value Score of F [10] - The Zacks Consensus Estimate for Aeva's 2025 earnings suggests a 21% year-over-year improvement [11]

Core Insights - Equinor is advancing its Snohvit Future project to significantly reduce CO2 emissions from oil and gas production on the Norwegian continental shelf, aiming to meet Paris Agreement targets [1][2][9] Group 1: Project Overview - The Snohvit Future project, approved in August 2023, aims to halve oil and gas production emissions by 2030 compared to 2005 levels, targeting a reduction of 850,000 tons of CO2 emissions annually, which represents about 2% of Norway's total yearly emissions [2][5] - The project involves electrifying Hammerfest LNG with power from the mainland and implementing onshore compression to achieve these emissions reductions [2][5] Group 2: Construction and Implementation - The electrification initiative includes the installation of three large modules at Hammerfest LNG: a compressor, a transformer station, and electrode steam boilers [3] - A major tunnel is being constructed to carry power cables, and Statnett is building a new 420 kV line to meet increased power demand [3][5] - Onshore compression is expected to begin by 2028, with full electrification targeted for 2030, which will extend the life of the Snohvit field and maintain energy supply to Europe through 2050 [5][9] Group 3: Collaboration and Contracts - Axess Group has won an enterprise of competence contract with Aibel, reinforcing their collaboration on Equinor's carbon-reducing efforts at the Hammerfest LNG facility [1][4] - Aibel is leading modification work at the site and has commenced inspection and testing of over 250 pieces of lifting equipment on the compressor module [4][6]

Company Information - 74Software is an enterprise software group formed by the merger of Axway and SBS, specializing in mission-critical software for a data-driven world [3] - Axway has been a pioneer in enterprise integration solutions for 25 years, providing services to major brands and government agencies globally [3] - SBS focuses on empowering banks and financial institutions with a cloud-based architecture for various financial services [3] - The company serves over 11,000 clients, including more than 1,500 in the financial services sector [3] Voting Rights and Shares - As of May 31, 2025, the total number of shares is 29,746,194 [5] - The total number of theoretical voting rights is 41,294,970 [5] - The number of exercisable voting rights is 40,813,565, which includes shares with suspended voting rights [1]

Core Viewpoint - Eli Lilly (LLY) is positioned as a strong long-term investment opportunity in the obesity treatment market, particularly with its GLP-1 drugs, despite potential competition and earnings growth slowdown risks. Group 1: Market Performance and Resilience - Eli Lilly's stock has shown relative resilience compared to the broader market, with a 19% decline during the 2022 inflation shock and a 23% decline during the 2020 COVID-19 pandemic, while the S&P 500 experienced declines of 25% and 34% respectively [2] - LLY stock has already absorbed significant impacts, falling over 20% from its 52-week high of over $970 to below $750 [3] Group 2: Market Potential and Competitive Position - The market for GLP-1 drugs is projected to grow to $150 billion by 2030, with Eli Lilly and Novo Nordisk currently dominating, having generated over $40 billion in sales last year [3] - Eli Lilly is a leader in the obesity treatment race, with superior efficacy and multiple product offerings, including injectable Zepbound and promising oral GLP-1 formulations showing nearly 8% weight loss in trials [3] Group 3: Financial Performance and Stability - Eli Lilly's growth rate is accelerating at over 30%, significantly higher than AbbVie's under 5%, with a three-year average growth rate of 17% compared to AbbVie's less than 1% [6] - Eli Lilly's three-year average margins stand at 34%, superior to AbbVie's 26%, indicating better profitability [6] - Eli Lilly's balance sheet is stronger, with debt making up only 4% of equity compared to AbbVie's 20%, signaling a healthier financial standing [6]

Economic Indicators - UBS has identified that recession risks in the United States are increasing, with three main indicators showing concerning trends: real-world data, credit conditions, and the yield curve [1][2] - The probability of a US recession based on real-world data has risen to 46%, an increase of 12 percentage points in just one month, indicating broad-based weakness in key economic areas [4][3] - The yield curve currently suggests an 18% probability of recession, which, while lower than previous extremes, still represents a notable increase [5] Credit Conditions - UBS's credit-based model indicates a 48% probability of recession, marking the highest level since the pandemic, reflecting shifts in financial ratios and lending conditions [6] Composite Recession Risk - The composite gauge from UBS places the overall US recession risk at 37%, up from 26% in December, approaching levels historically associated with actual downturns [7] - Despite these indicators, UBS does not currently predict a recession, noting that the economy began the year on stable footing, but warns that further data deterioration could reignite recession discussions [7] Global Implications - The US consumer remains a critical driver of global demand, and any retrenchment in consumer spending or business investment could negatively impact the developed world [9] - The situation is being closely monitored, with upcoming data in May and June expected to influence market narratives significantly [10]

Group 1: Company Performance - Barrick Mining Corporation experienced a significant decline in gold production in Q1 2025, producing 758,000 ounces, which is a 19% decrease year-over-year and a 30% decline from the previous quarter, marking the lowest quarterly output in recent years [1][7] - The decline in production was primarily due to the suspension of operations at the Loulo-Gounkoto mine amid a dispute with the Malian government, along with lower output from Carlin and Cortez [1][5] - The company expects 2025 gold production to be in the range of 3.15-3.5 million ounces, down from 3.91 million ounces in 2024, excluding potential restarts of the Loulo-Gounkoto mine [2][7] Group 2: Industry Comparison - Newmont Corporation reported an 8% year-over-year decline in gold production for Q1, reaching 1.54 million ounces, impacted by lower contributions from non-core operations [3] - Agnico Eagle Mines Limited saw a modest decline of around 0.5% in gold production to 873,794 ounces, but is on track to meet its 2025 target of 3.3-3.5 million ounces [4] Group 3: Financial Outlook - The Zacks Consensus Estimate for Barrick's earnings in 2025 and 2026 implies a year-over-year increase of 34.1% and 26.6%, respectively, with EPS estimates trending higher over the past 60 days [9] - Barrick is currently trading at a forward 12-month earnings multiple of 10.8, which is approximately a 21% discount compared to the industry average of 13.66X [10]

Core Insights - 60 Degrees Pharmaceuticals, Inc. announced results from an insurance claims analysis indicating a significant discrepancy between the number of Americans seeking reimbursement for babesiosis-related medical costs and CDC estimates of actual cases [1][2][10] - The company is investigating the true burden of babesiosis, particularly its association with chronic fatigue, through ongoing clinical trials and studies [6][8][10] Claims Analysis - Approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs annually, while CDC estimates only 2,000 cases in 2020 [2][10] - Claims data revealed that about 31% of babesiosis cases persist longer than 30 days, with nearly half of these cases associated with chronic fatigue lasting over six months [4][10] Chronic Fatigue Insights - Babesia infections can last at least 12 months in 14% of patients, with potential relapses occurring up to 27 months later [3] - Over three years, more than 12 million U.S. adults experienced chronic fatigue lasting more than six months, yet current guidelines do not mandate babesiosis as a differential diagnosis for such fatigue [5][10] Clinical Development - The company is conducting clinical trials to evaluate the safety and efficacy of tafenoquine in treating babesiosis, with data expected in the first half of 2026 [8][10] - A new drug application (NDA) for babesiosis is anticipated to be submitted to the FDA in 2026 [8][10] Product Information - Tafenoquine, marketed as ARAKODA, was approved for malaria prophylaxis in 2018 and is available as a prescription-only medication [9][10] - The drug has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [9]

SoFi Checking and Savings Member FDIC. APY up to 3.80% Rate info Circle with letter I in it. SoFi members who enroll in SoFi Plus with Eligible Direct Deposit or by paying the SoFi Plus Subscription Fee every 30 days or SoFi members with $5,000 or more in Qualifying Deposits during the 30-Day Evaluation Period can earn 3.80% annual percentage yield (APY) on savings balances (including Vaults) and 0.50% APY on checking balances. There is no minimum Eligible Direct Deposit amount required to qualif ...